The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 61 | 18.4x | 20.8x | Around median | |
Growth | 82 | 17.4% | 6.1% | Top tier | |
Quality | 78 | 10.9% | 6.6% | Top tier | |
Safety | 72 | 1.8x | 0.7x | Top tier | |
Capital Return | 77 | — | 2.02% | Top tier | |
Momentum | 1 | -55.0% | 4.1% | Bottom tier | |
Sentiment | 85 | 17 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Boston Scientific (BSX) is a leading global medical technology company specializing in the development and manufacturing of interventional medical devices used across a wide range of specialties. The company generates its revenue primarily through sales in its Cardiovascular, Electrophysiology (EP), Neuromodulation, Urology, and Endoscopy segments. The company relies heavily on its flagship products, such as the WATCHMAN Left Atrial Appendage Closure device and the FARAPULSE Pulsed Field Ablation system, to drive revenue growth and expand its global market share.
In the first quarter of fiscal year 2026, the company reported strong results with total revenue reaching $5.2 billion, representing 9.4% operational growth. The company recorded a gross profit of $3.6 billion, while net income reached $1.3 billion with EPS of $0.90, and adjusted EPS increased by 6% to reach $0.80. The company also maintained a strong adjusted operating profit margin of 28.8%, but despite these positive figures, management noted a slowdown in certain segments mid-quarter, prompting them to re-evaluate and lower their full-year guidance.
At the segment level, the Electrophysiology (EP) division achieved impressive organic growth of 22%, and the Neuromodulation segment grew by 15%. In contrast, the Urology segment faced significant headwinds, posting only 1% growth due to commercial disruptions in sacral neuromodulation sales and the impacts of the Volume-Based Procurement (VBP) program in China. Additionally, the WATCHMAN franchise recorded 19% growth, but saw a notable decline in standalone procedures, contributing to management's decision to adopt a more conservative outlook for the remainder of the year.
Boston Scientific stock currently trades at levels considered below fair value compared to Wall Street expectations, despite the recent reduction in financial guidance. Analysts hold a consensus buy recommendation for the stock, with an average price target of $79.1, indicating room for growth. Analyst targets range from a low of $55 to a high of $120, reflecting confidence in the ability of the company's product portfolio, such as FARAPULSE, to deliver long-term value that transcends short-term challenges.
Figures in the text are as of 2026-07-14; the live price is shown at the top of the page.
Despite achieving 9.4% operational growth and $5.2 billion in revenue in the first quarter, management noted an unexpected slowdown mid-quarter. This slowdown was concentrated in a decline in WATCHMAN standalone procedures, increased competition in the Electrophysiology segment, and weak performance in the Urology segment. Based on these three factors, the company decided to take a cautious stance and lower its full-year organic growth guidance to a range of 6.5% to 8.0%.
The WATCHMAN franchise achieved 19% organic growth during the first quarter of 2026, but faced pressure in standalone procedure volumes due to hospital capacity constraints. However, the company expects global growth in the mid-teens for this franchise for the full year. The company is relying on the highly positive results of the CHAMPION clinical trial to drive medical education and expand insurance coverage to bolster future growth.
The company is defending its leadership in the Pulsed Field Ablation (PFA) market through the continued expansion of FARAPULSE and OPAL systems usage, which resulted in 22% growth in the first quarter of 2026. Despite the entry of strong competitors like Johnson & Johnson, the company continues its significant investments in commercial and clinical capabilities. The company plans to launch the next-generation FARAWAVE Ultra catheter in the first half of 2027 to maintain its technological edge.
Automated analysis for informational purposes only — not investment advice.
The company places strategic acquisitions at the top of its priorities, which is evident in the pending Penumbra acquisition expected to close in the second half of 2026. Share repurchases come in second, as the Board of Directors approved a $5 billion program. Management has explicitly stated its intention to execute approximately $2 billion in share repurchases during the second quarter of 2026 to enhance shareholder value.